Immunocore (NASDAQ:IMCR) & Coeptis Therapeutics (NASDAQ:COEP) Head-To-Head Survey

Coeptis Therapeutics (NASDAQ:COEP) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations and institutional ownership.

Valuation & Earnings

This table compares Coeptis Therapeutics and Immunocore”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	N/A	N/A	-$21.27 million	($5.80)	-1.45
Immunocore	$310.20 million	4.86	-$55.29 million	($1.02)	-29.51

Coeptis Therapeutics has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 24.3% of Coeptis Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Immunocore shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Coeptis Therapeutics and Immunocore, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	0	1	0	0	2.00
Immunocore	1	4	6	0	2.45

Immunocore has a consensus target price of $59.44, indicating a potential upside of 97.49%. Given Immunocore’s stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than Coeptis Therapeutics.

Profitability

This table compares Coeptis Therapeutics and Immunocore’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	N/A	-1,094.50%	-219.97%
Immunocore	-15.87%	-12.84%	-5.09%

Volatility and Risk

Coeptis Therapeutics has a beta of -0.68, indicating that its stock price is 168% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Summary

Immunocore beats Coeptis Therapeutics on 9 of the 13 factors compared between the two stocks.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.